Prosecution Insights
Last updated: November 20, 2026

Nizal S Chandrakumar, USPTO Patent Examiner

Listed by the USPTO as CHANDRAKUMAR, NIZAL S

Tech Center 1600 • Art Units: 1625 1629 1674

This examiner grants 73% of resolved cases

Analysis

CHANDRAKUMAR, NIZAL S is associated with Tech Center 1600 and art unit 1625. The profile includes 1794 resolved cases, a 72.6% allowance rate, and a median of 835 days to allowance. The large case volume makes the outcome pattern useful for portfolio planning, and allowance occurs in a majority of recorded matters.

The interview lift is 18.3%, showing a higher observed allowance result for interviewed matters. Practitioners may use that relationship to support interview consideration while continuing to focus on claim language and prior-art distinctions. The leading companies are Revolution Medicines Inc., Beone Medicines I GmbH, and Nicoventures Trading Limited. The leading firms are BakerHostetler, Clark+Elbing LLP - Revolution Medicines, Inc., and FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

72.6%
Allow Rate
+12.6% vs TC avg
1,900
Total Applications
+18.3%
Interview Lift
835
Avg Prosecution Days
Based on 1794 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
11.0%
§102 Novelty
29.1%
§103 Obviousness
36.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17836814 ORAL PRODUCTS WITH REDUCED IRRITATION Final Rejection NICOVENTURES TRADING LIMITED
18700643 METHODS OF TREATING DISEASES ASSOCIATED WITH SENESCENT CELL ACCUMULATION Final Rejection University of Florida Research Foundation, Incorporated
18547871 DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC Final Rejection The Regents of the University of California
18777339 Benzimidazole Pyridine Derivatives Non-Final OA Hoffmann-La Roche Inc.
18604926 PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF Non-Final OA ALCON INC.
19106317 SUBSTITUTED PYRIDOPYRIMIDINONES Non-Final OA MIRATI THERAPEUTICS, INC.
18248364 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS Non-Final OA Regents of the University of Minnesota
18705232 PESTICIDALLY ACTIVE PYRIDAZINONE COMPOUNDS Final Rejection SYNGENTA CROP PROTECTION AG
18633298 Metal-Assisted Delayed Fluorescent Emitters Employing Benzo-imidazo-phenanthridine and Analogues Final Rejection Arizona Board of Regents on behalf of Arizona State University
18853224 IMMUNE MODULATORY AGENTS Non-Final OA PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18549852 METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS Non-Final OA AstraZeneca AB
18573813 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE Final Rejection Rutgers, The State University of New Jersey
18255749 OIL-IN-WATER EMULSIFIED COMPOSITION Non-Final OA KAO CORPORATION
17776922 METHODS OF INDUCING OR ENHANCING FARNESOID X RECEPTOR (FXR)-MEDIATED TRANSCRIPTIONAL RESPONSE Non-Final OA YALE UNIVERSITY
18684747 CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE Non-Final OA Bristol-Myers Squibb Company
18689222 METHOD FOR PRODUCING COMPOUND Final Rejection Mitsubishi Gas Chemical Company, Inc.
18746428 FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF Non-Final OA Praxis Precision Medicines, Inc.
18603755 Pyrazolopyridinone Compounds Non-Final OA Beigene Switzerland GMBH
18836681 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME Final Rejection Vertex Pharmaceuticals Incorporated
18569361 ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF Non-Final OA The University of Hong Kong
18788348 READY-TO-USE BARRIER AND KNOCKDOWN PESTICIDES Non-Final OA United Industries Corporation
18671477 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Non-Final OA Incyte Corporation
18577529 THE USE OF BETA-HYDROXYBUTYRATES FOR THE TREATMENT OR PREVENTION OF ANEURYSMS AND DISSECTIONS Non-Final OA Georgia State University Research Foundation, Inc.
18864033 COMPOSITIONS USEFUL FOR MODULATING SPLICING Non-Final OA Skyhawk Therapeutics, Inc.
17784972 COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF Final Rejection SIGILON THERAPEUTICS, INC.
17800049 HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS Non-Final OA Givaudan SA
18837146 HETEROCYCLIC GLP-1 AGONISTS Non-Final OA Gasherbrum Bio, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Nizal S Chandrakumar's allowance rate?

72.6% of resolved applications examined by Nizal S Chandrakumar were allowed (1,794 resolved cases), compared with 51.3% across Art Unit 1625 over the last five years.

Does an interview help with examiner Nizal S Chandrakumar?

This examiner's interview lift is +18.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Nizal S Chandrakumar take to allow a patent?

Applications allowed by Nizal S Chandrakumar took 835 days on average from filing to allowance.

Which art unit does examiner Nizal S Chandrakumar work in?

Nizal S Chandrakumar examines applications in Art Unit 1625 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month